J&J's TECVAYLI Shows Positive Data in First-Relapse Multiple Myeloma Trial (JNJ)

Johnson & Johnson reported positive results on May 29, 2026, from a Phase 3 trial of its bispecific antibody TECVAYLI (teclistamab-cqyv) in multiple myeloma patients at first relapse, a move that could expand the drug’s approved use into earlier treatment lines. The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival compared to standard-of-care regimens. TECVAYLI, targeting BCMA and CD3, is already approved for heavily pre-treated patients. Success in an earlier setting may unlock a larger market opportunity; analysts have forecast peak annual sales above $3 billion for the drug. J&J shares were little changed in pre-market activity. The company plans to present full data at a medical conference and file for a label expansion with the FDA.